The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effectiveness of triplet chemotherapy plus bevacizumab intensive regimen (FIr-B/FOx) and secondary liver surgery according to KRAS genotype in metastatic colorectal cancer (MCRC).
G. Bruera
No relevant relationships to disclose
K. Cannita
No relevant relationships to disclose
D. Di Giacomo
No relevant relationships to disclose
G. Troncone
No relevant relationships to disclose
A. Marchetti
No relevant relationships to disclose
G. Coletti
No relevant relationships to disclose
J. Sabourin
No relevant relationships to disclose
M. Tosi
No relevant relationships to disclose
C. Ficorella
No relevant relationships to disclose
E. Ricevuto
No relevant relationships to disclose